Puma Biotechnology
PBYI
188 hedge funds and large institutions have $5.13B invested in Puma Biotechnology in 2014 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 76 increasing their positions, 54 reducing their positions, and 31 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
41% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 54
29% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 31
3% more funds holding
Funds holding: 183 → 188 (+5)
1.47% more ownership
Funds ownership: 88.59% → 90.06% (+1.5%)
19% less capital invested
Capital invested by funds: $6.36B → $5.13B (-$1.23B)
28% less call options, than puts
Call options by funds: $33M | Put options by funds: $45.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$276M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$112M |
| 3 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$42.4M |
| 4 |
CCI
Columbus Circle Investors
|
+$25.6M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$171M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$94.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$71M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$63.8M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$40.9M |
PBYI Hedge Fund Activity: Q4 2014 in Review
188 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2014, worth a combined $5.13B — down 19% from $6.36B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new PBYI positions and 31 closed out — a net gain of 9 holders — while 76 added to existing stakes and 54 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $276M. The largest seller was T. Rowe Price Associates, cutting an estimated $171M.
- 188 institutional investors held Puma Biotechnology (PBYI) as of Q4 2014, up from 183 in Q3 2014.
- Funds reported $5.13B of Puma Biotechnology stock for Q4 2014, down 19% quarter-over-quarter.
- 40 funds opened new Puma Biotechnology positions in Q4 2014 and 31 closed out, a net change of +9 holders.
- The largest Puma Biotechnology buyer in Q4 2014 was Fidelity Investments, an estimated $276M added.
- The largest Puma Biotechnology seller in Q4 2014 was T. Rowe Price Associates, an estimated $171M sold.
Based on aggregated 13F filings for Q4 2014.